Identifying the prognostic significance of early arrhythmia recurrence during the blanking period and the optimal blanking period duration: insights from the DECAAF II study.
Arrhythmia recurrence
Atrial fibrillation
Atrial fibrillation burden
Blanking period
Catheter ablation
Journal
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
ISSN: 1532-2092
Titre abrégé: Europace
Pays: England
ID NLM: 100883649
Informations de publication
Date de publication:
02 06 2023
02 06 2023
Historique:
received:
13
04
2023
accepted:
12
06
2023
medline:
28
6
2023
pubmed:
20
6
2023
entrez:
20
6
2023
Statut:
ppublish
Résumé
Early atrial arrhythmia recurrence following atrial fibrillation (AF) ablation is common. Current guidelines promulgate a 3-month blanking period. We hypothesize that early atrial arrhythmia recurrence during the blanking period may predict longer-term ablation outcomes. A total of 688 patients with persistent AF undergoing catheter ablation were included in the DECAAF II trial database. The primary endpoint of the study was the first confirmed recurrence of atrial arrhythmia. Recurrence was also monitored during the 90-day blanking period. A total of 287 patients experienced recurrent atrial arrhythmia during the blanking period, while 401 remained in sinus rhythm. Rates of longer-term arrhythmia recurrence were substantially higher among those who developed recurrence during the blanking period compared to those who remained in sinus rhythm throughout the blanking period (68% vs. 32%, P < 0.001). The study cohort was divided into three groups according to the timing of arrhythmia recurrence during the blanking period. Of those who had recurrent arrhythmia during the first month of the blanking period (Group 1), 43.9% experienced longer-term recurrence, compared to 61.6% who recurred during the second month of the blanking period (Group 2), and 93.3% of those who had arrhythmia recurrence during the third month (Group 3, P < 0.001). The risk of recurrent arrhythmia was highest in Group 3 (HR = 10.15), followed by Group 2 (HR = 2.35) and Group 1 (HR = 1.5). Receiver operating characteristic analysis was performed to assess the relationship between the timing of arrhythmia recurrence and the primary outcome (AUC = 0.746, P < 0.001). The optimal blanking period duration was identified as 34 days. Atrial fibrillation burden determined by smartphone electrocardiogram technology over the 18 months follow-up period was significantly higher in Group 3 (29%) compared to Groups 1 (6%) and 2 (7%) and in patients who stayed in sinus rhythm during the blanking period (5%) (P < 0.0001). Early atrial arrhythmia recurrence during the blanking period, particularly during the third month, is significantly associated with later recurrence. Although a blanking period is warranted, it should be abbreviated.
Identifiants
pubmed: 37337683
pii: 7202423
doi: 10.1093/europace/euad173
pmc: PMC10292951
pii:
doi:
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medtronic
Organisme : GE
Organisme : Siemens
Organisme : Boston Scientific
Organisme : Biosense Webster
Organisme : Abbott
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
Déclaration de conflit d'intérêts
Conflict of interests: Dr Marrouche reported Marrek (founder) and from ECG Check (previous shareholder) outside the submitted work; and a patent issued for MRI fibrosis imaging. No other disclosures were reported.
Références
J Cardiovasc Electrophysiol. 2009 Oct;20(10):1089-94
pubmed: 19549038
Europace. 2022 Oct 13;24(10):1684-1690
pubmed: 35942585
Circulation. 2009 Sep 22;120(12):1036-40
pubmed: 19738139
Circ Arrhythm Electrophysiol. 2014 Feb;7(1):83-9
pubmed: 24446024
Circ Arrhythm Electrophysiol. 2011 Feb;4(1):11-4
pubmed: 21076158
J Cardiovasc Electrophysiol. 2012 Dec;23(12):1295-301
pubmed: 22897339
JAMA. 2022 Jun 21;327(23):2296-2305
pubmed: 35727277
Circ Arrhythm Electrophysiol. 2011 Dec;4(6):823-31
pubmed: 21930653
Europace. 2020 Dec 23;22(12):1759-1760
pubmed: 33197252
Int J Cardiol. 2021 Oct 15;341:39-45
pubmed: 34343532
Europace. 2022 Dec 9;24(12):1899-1908
pubmed: 35917218
Int J Cardiol. 2015 Nov 15;199:65-70
pubmed: 26186633
J Cardiovasc Electrophysiol. 2008 Jun;19(6):599-605
pubmed: 18462321
BMC Cardiovasc Disord. 2017 May 8;17(1):109
pubmed: 28482812
J Cardiovasc Electrophysiol. 2011 Jul;22(7):761-6
pubmed: 21385263
Heart Rhythm. 2016 Apr;13(4):845-51
pubmed: 26724490
Circ Arrhythm Electrophysiol. 2016 Aug;9(8):
pubmed: 27516462
Compr Physiol. 2015 Sep 20;5(4):1877-909
pubmed: 26426470
JACC Clin Electrophysiol. 2017 Jun;3(6):568-576
pubmed: 29759429
Heart Rhythm. 2017 Oct;14(10):e275-e444
pubmed: 28506916
Europace. 2020 Sep 1;22(9):1337-1344
pubmed: 32725107
Eur Heart J. 2016 Feb 14;37(7):610-8
pubmed: 26417061
Circ Arrhythm Electrophysiol. 2015 Aug;8(4):846-52
pubmed: 26108982
World J Cardiol. 2016 Nov 26;8(11):638-646
pubmed: 27957250